Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for reversal of neuromuscular blockade in pediatric patients younger than 2 years
2017-000693-11Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex and neostigmine in neuromuscular block (NMB) (2 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) for Sugammadex. Started Apr 2019; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2017-000693-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000693-11.